NASDAQ: BNGO · Industrial Applications and Services · 4 alerts · CIK 1411690
Share price
$0.9400Close, Nov 16
Market cap
$13.1M
Shares outstanding
13.99MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Laboratory Analytical InstrumentsSIC 3826
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Bionano Genomics, Inc. filings on SEC EDGAR ↗
BioNANO delivered 12% revenue growth driven by record flow cell sales and improved gross margins, while navigating supply constraints and targeting EBITDA neutrality by 2027.
Bionano Genomics reported total revenue of $8.28 million for the third quarter of 2026, a 12% increase year-over-year, while narrowing its quarterly net loss to $6.45 million compared to $8.50 million in 2025. The company's cash position remains tight, with total cash, cash equivalents, and investments decreasing significantly from $19.27 million at the end of 2025 to $8.17 million as of September 30, 2026.
Bionano Genomics reported Q3 2026 revenue of $8.3 million, a 12% increase year-over-year, driven by a 24% rise in consumables revenue. The company reiterated its full-year 2026 revenue guidance of $31 million to $33 million and highlighted progress in the clinical adoption of its optical genome mapping (OGM) technology.
Term
Q3 2026
“Our third quarter results reflect the momentum building across our business and the broader genomics community, further accelerating the adoption of optical genome mapping (OGM) in clinical and commercial settings.”
Al Luderer, Ph.D., chairman and interim chief executive officer
“Coverage and regulatory progress this quarter helped build a clearer reimbursement pathway for OGM-based testing, which we expect to support broader clinical adoption over time.”
Al Luderer, Ph.D., chairman and interim chief executive officer
Bionano Genomics Chairman and Interim CEO Al Luderer is presenting at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The company filed its conference presentation deck as an exhibit, which includes updates on its business strategy, optical genome mapping (OGM) adoption, and cost-saving initiatives. The presentation also addresses the company's focus on extending its cash runway and reaching a pathway to profitability.